Tafamidis (Vyndaqel®). HTA ID: 20017
Tafamidis (Vyndaqel®) is indicated for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy.
| NCPE Assessment Process | Complete |
| Rapid review commissioned | 30/03/2020 |
| Rapid review completed | 07/04/2020 |
| Rapid Review outcome | A full HTA is recommended to assess the clinical and cost effectiveness of tafamidis compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 29/04/2020 |
| Pre-submission consultation with Applicant | 18/05/2020 |
| Full submission received from Applicant | 01/07/2020 |
| Preliminary review sent to Applicant | 18/08/2020 |
| NCPE assessment recommenced | 10/09/2020 |
| Factual accuracy sent to Applicant | 11/09/2020 |
| NCPE assessment recommenced | 18/09/2020 |
| NCPE assessment completed | 25/09/2020 |
| NCPE assessment outcome | The NCPE recommends that tafamidis not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.